Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICG in Neonatal Cholestasis
NCT07250854Phase 1Recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Jan 2026
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of indocyanine green in biliary atresia and neonatal cholestasis, sponsored by University of Alabama at Birmingham. Primary endpoint: Number and accuracy of ICG fluorescence in the diagnosis of biliary atresia at 72 hours. Started Jan 2026; status: recruiting.
02
Drugs
indocyanine green
03
Conditions
biliary atresianeonatal cholestasis
Beyond the preview
Go deeper on NCT07250854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07250854.